Assistant Professor of Therapeutic Radiology; Chief, Genitourinary Radiotherapy Program, Therapeutic Radiology; Chief, Spine Radiotherapy Program, Therapeutic Radiology
Yale Gamma Knife® Center
- Metastatic brain tumors - Gamma Knife is as effective as surgery in controlling metastatic lesions. Control rates, on average, are 90 percent at one-year follow-up and 80 percent at two-year follow-up. However, Gamma Knife has the added benefit of being able to treat surgically inaccessible lesions and multiple lesions in one sitting. Unlike whole brain radiation therapy, it can also be used multiple times, if necessary, and it is compatible with ongoing chemotherapy.
- Benign brain tumors such as meningiomas, acoustic neuromas, pituitary adenomas and craniopharyngiomas - Compared to surgery, which can result in up to 20 to 40 percent recurrence rate at 10-year follow-up, radiosurgery controls tumors in more than 90 percent of cases at 10-year follow-up.
- Gamma Knife physicians collaborate with specialists in many diseases, including melanoma; lung cancer; breast cancer; gastrointestinal cancers such as colon cancer and esophageal cancer; genito-urinary cancers such as renal cell and prostate cancer; neurology and neurosurgery, hematology and pediatric surgery, to prepare the most effective treatment plans for our patients.
Contact: (203) 200-2000
Assistant Professor of Therapeutic Radiology
Associate Professor of Therapeutic Radiology; Chief, Gamma Knife Program, Therapeutic Radiology; Co-Director, Stereotactic Radiosurgery and Body Radiotherapy Fellowship, Therapeutic Radiology
Professor of Therapeutic Radiology